Li Qian, Liu Wei, Li Kai, Tian Yifu, Li Huan
Lung Hospital, Changsha Central Hospital, University of South China, Changsha, Hunan Province, People's Republic of China.
Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan Province, People's Republic of China.
Onco Targets Ther. 2021 May 13;14:3167-3175. doi: 10.2147/OTT.S300805. eCollection 2021.
Non-Hodgkin lymphoma can disseminate to the central nervous system at initiation of treatment for systemic lymphoma or spread during the relapse of systematic lymphoma with CNS involvement, which is defined as secondary central nervous system lymphoma (SCNSL). The incidence of SCNSL depends on the pathological type of lymphoma and is especially high in aggressive lymphoma. SCNSL has a poor prognosis because of the lack of effective treatment regimens. This article presents a rare case of SCNSL; an individualized treatment regimen was designed according to the genetic analyses of the patient tumor and included a Bruton's tyrosine kinase (BTK) inhibitor. After six cycles of treatment and another two cycles of rituximab, most lesions lost their metabolic activity. However, in the final stage of treatment, our patient unfortunately suffered from respiratory failure, which revealed that we should pay attention to pneumonia during ibrutinib treatment.
非霍奇金淋巴瘤可在系统性淋巴瘤治疗开始时播散至中枢神经系统，或在系统性淋巴瘤复发且累及中枢神经系统时扩散，这被定义为继发性中枢神经系统淋巴瘤（SCNSL）。SCNSL的发病率取决于淋巴瘤的病理类型，在侵袭性淋巴瘤中尤其高。由于缺乏有效的治疗方案，SCNSL的预后较差。本文介绍了一例罕见的SCNSL病例；根据患者肿瘤的基因分析设计了个体化治疗方案，其中包括布鲁顿酪氨酸激酶（BTK）抑制剂。经过六个周期的治疗以及另外两个周期的利妥昔单抗治疗后，大多数病灶失去了代谢活性。然而，在治疗的最后阶段，我们的患者不幸出现了呼吸衰竭，这提示我们在伊布替尼治疗期间应注意肺炎。
